硝唑烷
杀虫药
秀丽隐杆线虫
代谢物
药理学
生物
药品
传统医学
计算生物学
医学
遗传学
免疫学
生物化学
体外
基因
作者
Wenfeng Li,Shuming Chen,Jing Lang,Jinyong Luo,Jiahui Chen,Liping Zhang,Zeyu Sun,De‐Li Dong
标识
DOI:10.1016/j.apsb.2024.03.031
摘要
The drugs extending healthspan in clinic have always been searched. Nitazoxanide is an FDA-approved clinical antiprotozoal drug. Nitazoxanide is rapidly metabolized to tizoxanide after absorption in vivo. Our previous studies find that nitazoxanide and its metabolite tizoxanide induce mild mitochondrial uncoupling and activate cellular AMPK, oral nitazoxanide protects against experimental hyperlipidemia, hepatic steatosis, and atherosclerosis. Here, we demonstrate that both nitazoxanide and tizoxanide extend the lifespan and healthspan of C. elegans through Akt/AMPK/sir 2.1/daf16 pathway. Additionally, both nitazoxanide and tizoxanide improve high glucose-induced shortening of C. elegans lifespan. Nitazoxanide has been a clinical drug with a good safety profile, we suggest that it is a novel anti-aging drug.
科研通智能强力驱动
Strongly Powered by AbleSci AI